An Open, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration (wAMD)

An Open, Non-randomize, Single-center, Safety and Efficacy Study of Conbercept in Patients With Very Low Vision Secondary to Wet Age-related Macular Degeneration

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02098720

Acronym

LAMP

Enrollment

Registered

2014-03-28

Start date

2011-12-31

Completion date

Unknown

Last updated

2014-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Very Low Vision Secondary to Wet Age-related Macular Degeneration

Brief summary

This study is designed to evaluate the effect of Conbercept therapy on visual acuity and anatomic outcomes and safety observed in subjects with very low vision secondary to wet age-related macular degeneration.

Interventions

DRUGConbercept

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients give fully informed consent and are willing and able to comply with all study procedures. 2. In the study eye: There are primary or recurrent subfoveal or parafoveal active choroidal neovascularization (CNV) lesions secondary to wAMD. The criterion of active CNV should meet at least one of following three conditions : * fresh bleeding; * neurosensory detachment showed on optical coherence tomography(OCT); * leakage showed on fundus fluorescein angiography (FFA). 3. BCVA in study eye \< 19 letters (approximately 20/400 Snellen equivalent).

Exclusion criteria

1. Past or existing non-exudative AMD in study eye decided by investigator that have affected macular detection or central vision; 2. Subretinal hemorrhage in study eye and bleeding area ≥6 disc areas; 3. History of vitreous hemorrhage within last month; 4. The maximum diameter of scar and fibrosis area ≥500μm at subfoveal in study eye; 5. Photodynamic therapy (PDT) or drug treatment of CNV within last 6 months in study eye, or anti-vascular endothelial growth factor (VEGF) therapy in fellow eye within last month; 6. History of glaucoma in study eye; 7. Aphakia (excluding artificial lens) in the study eye.

Design outcomes

Primary

Measure	Time frame
percentage of patients with best corrected visual acuity (BCVA ) ≥19 letters gain	6-month

Secondary

Measure	Time frame	Description
mean change in BCVA from baseline	6-month	—
change from baseline of macular area thickness and other anatomy results	6-month	—
safety of Conbercept therapy	6-month	To assess incidence of adverse events, incidence of adverse drug reactions etc.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026